Signals
5Hyperemesis gravidarum therapy options widen past doxylamine-pyridoxine
Doxylamine-pyridoxine and ondansetron maturity, structured outpatient infusion pathways, and emerging GDF15-targeted programs are reshaping hyperemesis gravidarum management.
Genitourinary syndrome of menopause therapy widens past systemic hormone therapy
Vaginal estrogen formulation maturity, ospemifene and prasterone uptake, and emerging non-hormonal mechanism programs are restructuring genitourinary syndrome of menopause management.
Vasomotor symptom therapy expands past fezolinetant
Elinzanetant approval, follow-on NK3 receptor antagonist programs, and combination NK1-NK3 approaches are restructuring vasomotor symptom management.
Postmenopausal osteoporosis therapy reshapes around anabolic-first sequencing
Romosozumab maturity, ongoing teriparatide and abaloparatide use, and follow-on anabolic programs are restructuring postmenopausal osteoporosis sequencing.
Fertility therapy moves from procedural to pharmacological
Pharmacological adjuncts and oocyte-quality interventions are expanding the fertility-therapy toolset beyond the IVF procedural footprint.
Snapshots
2Maternal mental health pipeline, 2026 mid-year reference
Reference layout of the maternal mental health pipeline as of mid-2026: approved mechanisms for postpartum depression, late-stage assets for perinatal mood disorders and adjacent indications, and the live commercial questions including screening pathway and access frame.
Endometriosis pipeline, 2026 mid-year reference
Reference layout of the endometriosis pipeline as of mid-2026: approved mechanisms, late-stage assets, the GnRH antagonist class, the non-hormonal pipeline, and the live commercial questions including diagnosis-pathway access and the surgical-medical interplay.